Correlation Engine 2.0
Clear Search sequence regions

  • BCR ABL (1)
  • child (2)
  • dasatinib (3)
  • diagnosis (1)
  • humans (1)
  • leukemia (7)
  • philadelphia (6)
  • prognosis (1)
  • Sizes of these terms reflect their relevance to your search.

    The addition of tyrosine kinase inhibitors to conventional chemotherapy has improved outcomes for pediatric patients with Philadelphia chromosome-positive (Ph) acute lymphoblastic leukemia (ALL). However, the rate of relapse is still higher compared with many other types of pediatric ALL, with many possible mechanisms for resistance. We describe an 8-year-old boy with Ph ALL relapsing with ALL without the Ph following treatment with dasatinib as a part of Children's Oncology Group trial AALL1122. This emphasizes the polyclonal nature of ALL at diagnosis and indicates that the BCR-ABL fusion oncogene is not always an essential "driver" mutation.


    Casey J Mehrhoff, Charles S Hemenway, Eugene Suh. Emergence of a Ph-negative Clone in a Child With Ph+ ALL. Journal of pediatric hematology/oncology. 2020 Aug;42(6):e466-e468

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 31149920

    View Full Text